The affected products, bevacizumab injectable and bevacizumab normject TB injectable, were distributed to 38 states, Washington, D.C., and Puerto Rico.
The pharmacy is recalling all lots of the products due to concerns over a lack of sterility. The FDA issued a formal request in late August to AmEx Pharmacy to recall all of its compounded drug products intended to be sterile after the company failed to take corrective actions when an inspection found “significant quality and sterility concerns.”
The pharmacy is notifying its customers and arranging for the return of all recalled products.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
